193 related articles for article (PubMed ID: 31791289)
1. PPARα ligand, AVE8134, and cyclooxygenase inhibitor therapy synergistically suppress lung cancer growth and metastasis.
Wu L; Wang W; Dai M; Li H; Chen C; Wang D
BMC Cancer; 2019 Dec; 19(1):1166. PubMed ID: 31791289
[TBL] [Abstract][Full Text] [Related]
2. AVE8134, a novel potent PPARα agonist, improves lipid profile and glucose metabolism in dyslipidemic mice and type 2 diabetic rats.
Schäfer HL; Linz W; Falk E; Glien M; Glombik H; Korn M; Wendler W; Herling AW; Rütten H
Acta Pharmacol Sin; 2012 Jan; 33(1):82-90. PubMed ID: 22212431
[TBL] [Abstract][Full Text] [Related]
3. The peroxisome proliferator-activated receptor-alpha (PPAR-alpha) agonist, AVE8134, attenuates the progression of heart failure and increases survival in rats.
Linz W; Wohlfart P; Baader M; Breitschopf K; Falk E; Schäfer HL; Gerl M; Kramer W; Rütten H
Acta Pharmacol Sin; 2009 Jul; 30(7):935-46. PubMed ID: 19503102
[TBL] [Abstract][Full Text] [Related]
4. PPARα activation can help prevent and treat non-small cell lung cancer.
Skrypnyk N; Chen X; Hu W; Su Y; Mont S; Yang S; Gangadhariah M; Wei S; Falck JR; Jat JL; Zent R; Capdevila JH; Pozzi A
Cancer Res; 2014 Jan; 74(2):621-31. PubMed ID: 24302581
[TBL] [Abstract][Full Text] [Related]
5. Cytochrome P450 eicosanoids are activators of peroxisome proliferator-activated receptor alpha.
Ng VY; Huang Y; Reddy LM; Falck JR; Lin ET; Kroetz DL
Drug Metab Dispos; 2007 Jul; 35(7):1126-34. PubMed ID: 17431031
[TBL] [Abstract][Full Text] [Related]
6. Peroxisomal proliferator-activated receptor-alpha-dependent inhibition of endothelial cell proliferation and tumorigenesis.
Pozzi A; Ibanez MR; Gatica AE; Yang S; Wei S; Mei S; Falck JR; Capdevila JH
J Biol Chem; 2007 Jun; 282(24):17685-95. PubMed ID: 17405874
[TBL] [Abstract][Full Text] [Related]
7. Role of cytochrome P450-dependent arachidonic acid metabolites in liver physiology and pathophysiology.
Sacerdoti D; Gatta A; McGiff JC
Prostaglandins Other Lipid Mediat; 2003 Oct; 72(1-2):51-71. PubMed ID: 14626496
[TBL] [Abstract][Full Text] [Related]
8. 20-Hydroxyeicosatetraenoic acid inhibits ATP-induced COX-2 expression via peroxisome proliferator activator receptor-α in vascular smooth muscle cells.
Liang CJ; Tseng CP; Yang CM; Ma YH
Br J Pharmacol; 2011 Jun; 163(4):815-25. PubMed ID: 21323895
[TBL] [Abstract][Full Text] [Related]
9. Dietary linoleic acid-stimulated human breast cancer cell growth and metastasis in nude mice and their suppression by indomethacin, a cyclooxygenase inhibitor.
Connolly JM; Liu XH; Rose DP
Nutr Cancer; 1996; 25(3):231-40. PubMed ID: 8771566
[TBL] [Abstract][Full Text] [Related]
10. The anti-tumorigenic properties of peroxisomal proliferator-activated receptor alpha are arachidonic acid epoxygenase-mediated.
Pozzi A; Popescu V; Yang S; Mei S; Shi M; Puolitaival SM; Caprioli RM; Capdevila JH
J Biol Chem; 2010 Apr; 285(17):12840-50. PubMed ID: 20178979
[TBL] [Abstract][Full Text] [Related]
11. Inhibitors of the arachidonic acid pathway and peroxisome proliferator-activated receptor ligands have superadditive effects on lung cancer growth inhibition.
Avis I; Martínez A; Tauler J; Zudaire E; Mayburd A; Abu-Ghazaleh R; Ondrey F; Mulshine JL
Cancer Res; 2005 May; 65(10):4181-90. PubMed ID: 15899809
[TBL] [Abstract][Full Text] [Related]
12. Peroxisome-proliferator-activated receptor alpha agonists inhibit cyclo-oxygenase 2 and vascular endothelial growth factor transcriptional activation in human colorectal carcinoma cells via inhibition of activator protein-1.
Grau R; Punzón C; Fresno M; Iñiguez MA
Biochem J; 2006 Apr; 395(1):81-8. PubMed ID: 16343055
[TBL] [Abstract][Full Text] [Related]
13. PPARalpha agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition.
Panigrahy D; Kaipainen A; Huang S; Butterfield CE; Barnés CM; Fannon M; Laforme AM; Chaponis DM; Folkman J; Kieran MW
Proc Natl Acad Sci U S A; 2008 Jan; 105(3):985-90. PubMed ID: 18199835
[TBL] [Abstract][Full Text] [Related]
14. PPARα agonist alleviates tumor growth and chemo-resistance associated with the inhibition of glucose metabolic pathway.
Gou Q; Dong C; Jin J; Liu Q; Lu W; Shi J; Hou Y
Eur J Pharmacol; 2019 Nov; 863():172664. PubMed ID: 31539552
[TBL] [Abstract][Full Text] [Related]
15. Cyclooxygenase inhibitors retard murine mammary tumor progression by reducing tumor cell migration, invasiveness and angiogenesis.
Rozic JG; Chakraborty C; Lala PK
Int J Cancer; 2001 Aug; 93(4):497-506. PubMed ID: 11477553
[TBL] [Abstract][Full Text] [Related]
16. PPARalpha agonists suppress osteopontin expression in macrophages and decrease plasma levels in patients with type 2 diabetes.
Nakamachi T; Nomiyama T; Gizard F; Heywood EB; Jones KL; Zhao Y; Fuentes L; Takebayashi K; Aso Y; Staels B; Inukai T; Bruemmer D
Diabetes; 2007 Jun; 56(6):1662-70. PubMed ID: 17360982
[TBL] [Abstract][Full Text] [Related]
17.
Hashimoto R; Joshi SR; Jiang H; Capdevila JH; McMurtry IF; Laniado Schwartzman M; Gupte SA
Am J Physiol Heart Circ Physiol; 2017 Aug; 313(2):H293-H303. PubMed ID: 28550179
[TBL] [Abstract][Full Text] [Related]
18. Barbigerone, an isoflavone, inhibits tumor angiogenesis and human non-small-cell lung cancer xenografts growth through VEGFR2 signaling pathways.
Li X; Wang X; Ye H; Peng A; Chen L
Cancer Chemother Pharmacol; 2012 Sep; 70(3):425-37. PubMed ID: 22814678
[TBL] [Abstract][Full Text] [Related]
19. Monascin and ankaflavin act as natural AMPK activators with PPARα agonist activity to down-regulate nonalcoholic steatohepatitis in high-fat diet-fed C57BL/6 mice.
Hsu WH; Chen TH; Lee BH; Hsu YW; Pan TM
Food Chem Toxicol; 2014 Feb; 64():94-103. PubMed ID: 24275089
[TBL] [Abstract][Full Text] [Related]
20. Nimesulide, a preferential cyclooxygenase 2 inhibitor, suppresses peroxisome proliferator-activated receptor induction of cyclooxygenase 2 gene expression in human synovial fibroblasts: evidence for receptor antagonism.
Kalajdzic T; Faour WH; He QW; Fahmi H; Martel-Pelletier J; Pelletier JP; Di Battista JA
Arthritis Rheum; 2002 Feb; 46(2):494-506. PubMed ID: 11840453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
